On June 1, 2022 OncoNano Medicine, Inc. reported the appointment of Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer (Press release, OncoNano Medicine, JUN 1, 2022, View Source [SID1234615330]). Dr. Krishnan will be responsible for formulating and leading all clinical development efforts and operations at OncoNano. Additionally, Dr. Krishnan will develop and implement the strategic clinical plans for OncoNano, including the creation of a medical affairs team, as the company further advances its clinical oncology development programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled that OncoNano has been successful in attracting such a noted and impressive scientist as Dr. Krishnan. Kartik is a proven and respected oncology drug developer, with extensive experience in leading the development of novel oncology therapeutic programs," said Martin Driscoll, CEO of OncoNano. "His breadth of experience and history of drug development success will be instrumental to our company as we progress our differentiated portfolio of oncology development candidates into multiple clinical trials."

Dr. Krishnan previously served as Chief Medical Officer at Arcus Biosciences, where he led the expansion of the company’s portfolio into novel indications and combinations, as well as the initiation of a number of pivotal Phase 3 trials. Prior to joining Arcus, he served as Executive Medical Director at Astex Pharmaceuticals, providing strategic direction and tactical support across multiple programs in all phases of development. Dr. Krishnan has also held positions in clinical drug development at Genentech, FivePrime Therapeutics, BioMarin and Amgen. Dr. Krishnan earned both his M.D. and Ph.D. in Cellular, Molecular, and Biophysical Studies from Columbia University.

"My passion is working with novel technologies that have the potential to benefit the treatment of patients with cancer. I am excited about the potential for the core platform technology at OncoNano that can deliver oncology payloads in a targeted and efficient manner to the tumor microenvironment," said Dr. Krishnan. "I believe I am joining OncoNano at an ideal time because I can immediately impact the strategic development plans for the OncoNano therapeutics programs and lead the execution of the clinical programs at the company. I am impressed with the OncoNano organization and look forward to working with Marty and the OncoNano team to successfully advance our pipeline and achieve the company’s mission to benefit cancer patients."

On June 1, 2022 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, reported members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022 (Press release, Aadi Bioscience, JUN 1, 2022, View Source [SID1234615329]). Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fireside chat at 10am ET on Thursday, June 9, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the "Event Calendar" page within the Investors & News section of the Company’s website at www.aadibio.com. A replay of the webcast will be available for approximately 30 days following the presentation.

On June 1, 2022 Monteris Medical reported that a paper on laser interstitial thermal therapy (LITT) for patients diagnosed with IDH wild–type glioblastoma, the most common and aggressive tumor originating in the brain, has been published in the journal, Neuro- Oncology Advances (Press release, Monteris Medical, JUN 1, 2022, https://www.monteris.com/press-releases/monteris-medical-announces-publication-of-largest-cohort-to-date-of-litt-for-treating-most-aggressive-brain-tumor/ [SID1234615327]). The data on 89 patients collected through the LAANTERN prospective, multi-center registry, showed that LITT offers an effective alternative to traditional surgery for patients with newly diagnosed and recurrent glioblastoma while also delivering the benefits of a minimally invasive surgical procedure, including short recovery time and reduced potential for side effects.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication demonstrated that for newly diagnosed patients treated with LITT followed by standard of care chemotherapy and radiation, overall survival (16.14 months) and progression free survival (11.93 months) are comparable to published outcomes where traditional surgery was used. For patients with recurrent disease, no standard of care is currently established; however, this study showed median post-LITT survival of nearly nine months, compared to the range of 5-13 months observed for traditional surgery. In addition, the functional status of patients stabilized or improved at one month post-LITT.

IDH (isocitrate dehydrogenase – a genetic mutation) wild-type glioblastomas require immediate intervention. With standard of care therapy, median overall survival for glioblastoma is estimated at 15-18 months with fewer than 10% of patients alive at five years. Other molecularly defined gliomas may be less prevalent than IDH wild-type, but they are known to have longer survival rates. Therefore, it is becoming increasingly important to stratify research by sub-type and molecular characteristics to control for the variability in survival rates across all glioma types.

Dr. John de Groot, lead author of the paper and division chief of neuro-oncology at the University of California San Francisco Weill Institute for Neurosciences, said, "For patients with glioblastoma, treatment options are limited, especially for those with recurrent disease. These data clearly demonstrate that LITT remains a critical tool for achieving maximal safe cytoreduction of the tumor and is especially effective when followed by chemotherapy and radiation. The minimally invasive nature of LITT, short recovery, and favorable side effect profile make LITT a safe and effective option."

About 25,000 primary brain tumors are diagnosed in the United States each year. Of these, about 15% are glioblastomas. Those glioblastomas that are moleculary-defined as IDH wild-type tend to grow rapidly and have a worse prognosis than other tumor types.

Martin J. Emerson, president and chief executive officer of Monteris, said, "Congratulations to the LAANTERN physicians and their research teams on the publication of this essential study on LITT and primary brain tumors. We are so grateful to the patients that gave their time and energy to participate in this study. The collective body of evidence that continues to emerge in support of laser ablation has firmly established LITT’s position in the care continuum for appropriate brain tumor and epilepsy patients."

About LAANTERN

LAANTERN is a post-market study designed to evaluate the performance and utilization of the NeuroBlate System in the standard of care, "real-world" setting. This is the first prospective multicenter laser ablation study. All sites operate under an IRB-approved protocol and undergo rigorous data management and monitoring practices to ensure data quality and consistency. The registry will follow up to 3,000 patients for five years evaluating safety, quality of life, health economics and procedural outcomes, including survival and seizure freedom.

On June 1, 2022 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL (Press release, Biodesix, JUN 1, 2022, View Source [SID1234615326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

42nd Annual William Blair Growth Stock Conference
Date: Wednesday, June 8, 2022
Time: 9:20 a.m. CT

In addition to the presentation, the management team will host investor meetings. Investors participating in the conference who are interested in meeting with Biodesix management should contact their William Blair representative.

A live webcast of the presentation will be available under "News & Events" in the Investors section of the Company’s website at www.biodesix.com. A replay will be available for 90 days following the event.

On June 1, 2022 ADC Therapeutics SA (NYSE: ADCT) reported that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET (Press release, ADC Therapeutics, JUN 1, 2022, View Source [SID1234615325]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.